---
title: "SpringWorks Therapeutics may be worth around $77 a share in a takeover - analyst"
date: "2025-02-10 21:43:08"
summary: "SpringWorks Therapeutics (NASDAQ:SWTX) may be valued at about $77 a share in a possible takeover after a report earlier that Merck KGaA (OTCPK:MKGAF) is in talks for a purchase of the cancer and rare disease drugmaker, according to a Wedbush analyst. SpringWorks (NASDAQ:SWTX) shares surged 38% after a Reuters report..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196203326/image_1196203326.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

SpringWorks Therapeutics (NASDAQ:[SWTX](https://seekingalpha.com/symbol/SWTX "SpringWorks Therapeutics, Inc.")) may be valued at about $77 a share in a possible takeover after a report earlier that Merck KGaA ([OTCPK:MKGAF](https://seekingalpha.com/symbol/MKGAF "Merck KGaA")) is in talks for a purchase of the cancer and rare disease drugmaker, according to a Wedbush analyst.

SpringWorks (NASDAQ:[SWTX](https://seekingalpha.com/symbol/SWTX "SpringWorks Therapeutics, Inc.")) shares surged 38% after a Reuters report about German drugmaker's  [acquisition talks.](https://seekingalpha.com/news/4405616-springworks-therapeutics-jumps-on-report-of-merck-kgaa-takeover-talks " acquisition talks. ") If an agreement is reached, it could be signed in the coming weeks, according to the report."While we have no doubts about SWTXâ€™s ability to build out its commercial franchises on its own, a buyout could make more sense for shareholders depending on the price," Wedbush analyst David Nierengarten wrote in a note on Monday.

Nierengarten expects that a deal for SpringWorks ([SWTX](https://seekingalpha.com/symbol/SWTX "SpringWorks Therapeutics, Inc.")) would be near his target price of $77 a share, representing a 92% premium to SWTX's closing price on Friday.

The Wedbush analyst highlighted that deal premiums for recent transaction for SMID cap biotechs with approved assets have ranged from 60% to 110% premiums.

[seekalpha](https://seekingalpha.com/news/4405716-springworks-therapeutics-may-be-worth-around-77-a-share-in-a-takeover-analyst)
